Status:
COMPLETED
Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma
Lead Sponsor:
University of Michigan Rogel Cancer Center
Conditions:
Sarcoma, Soft Tissue
Eligibility:
All Genders
10+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to explore how a sarcoma is affected by and the side effects of a newer combination of chemotherapy drugs(gemcitabine and docetaxel)as compared to a standard combination o...
Detailed Description
The purpose of this study is to explore the relative activity and toxicity of a newer combination of chemotherapy drugs, gemcitabine and docetaxel, as compared to a standard combination of chemotherap...
Eligibility Criteria
Inclusion
- no evidence of metastasis
- soft tissue sarcoma
- intermediate or high histologic grade
- greater than 5 cm
- Zubrod performance status 1 or better
- age 10 or older
Exclusion
- clear cell, alveolar soft part, Ewing's rhabdosarcoma, undifferentiated small cell or Kaposi's
- prior chemotherapy
- nephrectomy
- active unstable angina pectoris
- concurrent therapy
Key Trial Info
Start Date :
August 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2015
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT00189137
Start Date
August 1 2004
End Date
October 1 2015
Last Update
December 7 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States, 48109